Ed Zhang
Co-Founder & Chief Executive Officer Overland Pharmaceuticals
Ed Zhang is founding CEO of Overland Therapeutics and co-founded its predecessor, Overland Pharma, while serving as a venture partner at Hillhouse Investment in 2020, becoming CEO in 2022. He brings over 20 years of biopharma industry experience across scientific research, business development, strategy, and general management. Previously, he was VP Corporate Development at Boston Pharmaceuticals, leading strategic initiatives, and held roles at Sanofi’s Specialty Products BU and Genzyme prior to its acquisition by Sanofi. He began his career as a medicinal chemist at Pharmacia & Upjohn and holds a B.S. from Nanjing University and an M.B.A. from Northwestern University.
Seminars
Thursday 17th September 2026
Roundtable Discussion: Navigating Regulatory Expectations for Next-Generation Cell Therapies to Accelerate Translation to the Clinic
2:45 pm
- Discussing evolving regulatory requirements for CAR-T, TCR, cell therapies to align with compliance standards
- Exploring how regulators are adapting to next-generation modalities, including in vivo delivery and manufacturing innovations
- Identifying strategies to design development programs that meet regulatory expectations while accelerating clinical translation
Thursday 17th September 2026
Highlighting Overland Therapeutics’ GPRC5D/BCMA Dual CAR-T Clinical Data
5:00 pm
